华侨大学教授(图)福建晋江人，分子药物教育部工程研究中心主任（立项）、教授、博士生导师、华侨大学分子药物学研究所所长、Otago 大学博士、北京协和医学院荣誉教授、国际癌细胞与基因疗法学会常务理事、新西兰食品科学技术研究院专业委员、爱尔兰国家自然基金评审专家、《中国临床药理学和治疗学》编委、顾问、山东大学兼职教授、“行政院”台北荣民总院荣誉教授、中国海洋大学海洋药物客座教授，国家863“十五”肺癌基因疗法课题组组长、首席科学家、肝癌基因疗法课题组副组长、为口服基因疗法主要奠基人之一。1983年考上教育部公派留学。从事分子药学，分子药理学和医学生物工程技术研究。部分分子药学研究工作发表于Nature Medicine、Science、PNAS等国际一流学术刊物。近10年来发表论文50篇，其中SCI国际论文38篇（影响因子>250分），并申报美国、中国专利9项。主编《分子基因药物学》（北京大学出版社 &北京大学医学出版社）2008年2月，《细胞工程与生物技术》，合编《Trends in Gene Therapy Research》NOVA Science Publisher, New York, USA(2005)。
PATENT APPLICATIONS:(8)
u Xu RA*, Li XY, Fung PCW. Compositions and methods for preventing and treating liver cirrhosis（Non-provisional Application Number: 60/473992; Lodge date: May 28, 2004, New York, USA, China）.
u Xu RA*, Shi J, Zheng D, Liu Y. TRAIL for lung cancer therapy (Regular Application Number: 11/330,450 USA)
u Zheng D, Xu RA*, Liu Y, Ma H AAV/TRAIL for liver cancer therapy (2003, China)
u Xu RA* Diao Y, Wang G Preparation and application of cytoglubin Non-provisional Application Number: 200510094205.1; China)
u Xu RA*, Diao Y, Tse L-Y Two novel anti-angiogenic inhibitors for liver cancer therapy (Non-provisional Application Number: 2005101349792; China)
u Xu RA* Fung P, Chu KW Two anti-angiogenic inhibitors for colon cancer therapy (Non-provisional Application Number: 200610097384.9; China)
u Xu RA*, Diao Yong Compositions and methods for preventing thrombus (Non-provisional Application Number: 2006100857392; China)
u 曾庆友，许瑞安 肉桂酸乙酯衍生物的绿色合成工艺 中国专利2007年 公开申请号：
PUBLICATIONS
I. Total Chapters of Books: 15
1. 1 Chapter Xu RA* et al. Oral viral gene delivery （33pages）,
In: Trends in Gene Therapy Research （2005） NOVA SCIENCE
Publisher, New York, USA （An invitation to Xu RA from NOVA
Science Publisher, New York, USA）
2. 9 Chapters In: Molecular Gene Medicine Xu RA*, Chen L, Xiao WD
(Es), Peking University Press & Peking University
Medical Press, 2008.2
许瑞安＊ 陈凌、肖卫东 主编《分子基因药物学》.北京大学出版社 & 北京大学医学出版社2008.2
3. 5 Chapters In: Cell Engineering and Biotechnology Diao Y, Xu RA* (Es)
Chemical Industry Press, Peking, 2008.4
刁勇、许瑞安＊ 主编 《细胞工程与生物技术》化学工业出版社 2008年4月
II. Review Papers
1. Total Review Papers (>80);
2. List of Recent 10-year Peer Review Articles
( Total：50；SCI：38，Total Impact Factor：251.8，IF=6.6/paper ):
u Wang Q, Lv Y, Xu R*. The design of vectors for RNAi delivery system. Curr Pharm Design 2008 (In press). (IF5.17) (An invitation from Editor-in-chief to Xu RA)
u Tse LY，Sun X*, Jiang H, Dong X, Fung PWC, Farzaneh F, Xu R*. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular varcinomas. J Gene Med 2008, 10 (In press) (IF3.92)
u Li H, Li XY, Lam, KS, Cheung T, Xu RA* Adeno-associated virus-mediated pancreatic and duodenalmhomeobox gene-1 expression enhanced differentiation of hepatic oval stem cells to insulin-producing cells in diabetic rats. J Med Sci, 2008 (in press) (IF2.1)
u Cai, K, Tam P, Xu RA, Shan MH. Suppression of lung tumor metastasis in mice by recombinant adeno-associated virus-mediated expression of vasostatin Clin Cancer Res 2008, (in press) (IF 6.2)
u Rabie AB, Dai J, Xu RA. Recombinant adeno-associated virus mediated vascular endothelial growth factor gene therapy induces mandibular condylar growth. Gene Ther 2007, 14, 972–980 (IF 5.0).
u Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu RA, Sun X. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer 2007, 121(2):416-24 (IF 4.69)
u Wang D, Liu W, Han B, Xu R. Biochemical and enzymatic properties of a novel marine fibrinolytic enzyme from Urechis unicinctus. Appl Biochem Biotech 2007 136(3):251-64.(IF 1.10)
u Xu RA, Harrison, PM, Chen, M,Li, XY, Tsui T-Y, Fung PCW, Cheung P-T, Guangji Wang G, Li H, Diao Y, Xu S, Krissansen GW, Farzaneh F. Cytoglobin protects against damage-induced liver fibrosis. Mol Ther 2006, 13(6):1093-100 (IF 5.7)
u Xu RA, Zhao B, Fung P, Li XY. Histology and histopathology 2006，21：587-92(IF 2.1)(An invitation from Editor-in-chief, Professor Hernz-calvo to Xu RA)
u Bernd H, Xu RA, Xie J, Ding Q, Sipler M, Wang H, Chen, L, Xiao WD. An efficient AAV1/AAV2 hybrid vector for gene therapy of Hemophilia. Human Gene Therapy 2006, 17(1):46-54.(IF 5.10)
u Ma H, Liu Y, Liu S, Xu RA*, Zheng D*. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005, 42(6):1355-63.(IF 10.4)
u Shi J, Liu Y, Guo J, Zhang D, Zheng D, Li X, Cheung P-t, Farzaneh F, Xu RA*.Expression of an anti-DR5 single chain antibody in muscles of nude mice prevents lung cancer growth. Cancer Res 2006, 66(24):11946-53. (IF 8.7)
u Lee TK, Man K, Ho JW, Wang HX, Poon RT, Sun KW, Ng KT, Ng IO, Xu RA, Fan ST. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005, 11(23):8458-66.(IF 5.7)
u Tsui TY, Lau CK, Wu X, Wang YQ, Siu YT, Xu RA, Schlitt HJ, Fan ST Hemo oxygnase-1 gene therapy attenuates micronodular Liver cirrhosis in rat. Hepatology 2005, 42(2):335-42.(IF 10.4)
u Ma H, Zheng D*, Liu Y, Liu S, Kung HF, Sun X, Xu RA*. AAV-Mediated TRAIL gene therapy suppresses liver metastatic tumors. International Journal of Cancer 2005, 116(2):314-21.(IF 4.5)
u Chen M, Wang GJ, Diao Y, Xie H, Li X, Sun J, Xu RA. AAV-mediated interferon-gamma ameliorates the hepatic fibrosis in vitro and in vivo. World J Gastroenterology 2005, 11(26):4045-51.(IF 2.8)
u Wang DL, Hu Q, Xu RA*. The bioreactor: a powerful tool for large-scale preparation for animal cells. Curr Pharm Biotech 2005, 6(5):397-403.
u Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu RA*. Over-expression of soluble tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005, 65:1687-92.(IF 8.7)
u Sun X, Qiao H, Jiang H, Zhi X, Liu F, Wang J, Liu M, Dong D, Kanwar JR, Xu RA, Krissansen GW. Intramuscular delivery of anti-angiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther 2005, 12 (1) 35-45.(IF 3.1)
u Xu RA*, Ma H, Fung PCW, Chang Q, Xu S, During MJ Stability of infectious recombinant AAV vector. Medical Science Monitor 2005, 11(9) BR305-308
u Dai J, Rabie AB, Hagg, EUO, Xu RA*. A novel strategy for repair of craniofacial bone defects. Curr Gene Ther 2004, 4(4):469-85; (IF 3.68).
u Lee TK, Man K, Ho JW, Wang HX, Poon RT, Sun KW, Ng KT, Ng IO, Xu RA, Fan ST. The significance of RAC-signaling pathway in HCC cell motility: Implication for a new therapeutic target. Carcinogenesis 2005,26(3):681-7(IF 5.3)
u Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu RA, Fan ST. FTY 720 induce apoptosis of human hepatoma cell lines through PI3-K mediated Akt dephosphorylation. Carcinogenesis 2004, 25 (12) 2397-405.(IF 5.3)
u Ma H, Liu YX, Liu SL, Xu RA, Zheng DX. Expression of TRAIL (114-281) mediated by adeno-associated virus and its tumoricidal activity. Zhonghua Yi Xue Za Zhi 2004, 84 (19):1635-41. (IF 0.3)
u Tu SP, Cui JT, Liston P, Jiang XH, Xu RA, Lin MCM, Zhu YB, Zou B, Samuel SM Ng, Xia HX, Wong WM, Chan OO, Yuen MF, Lam SK, Kung HF, Wong BCY. Gene therapy for colon cancer by adeno-associated virus-mediated transfer of surviving Cys84Ala mutant. Gastroenterology 2005, 128 (2): 361-75.(IF 13.05)
u Sun X, Krissansen GW, Fung PWC, Xu S, Shi J, Man K, Fan ST, Xu RA*. Anti-angiogenic therapy subsequent to adno-associated virus mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int J Cancer 2005, 113 (4) 670-7.(IF 4.5)
u Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, Farkas S, Xu R, Schlitt HJ, Fan ST. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: A new approach to attenuate liver fibrosis in rats. Hepatology 2005: 335-42(IF 10.4).
u Xu RA*, Sun X, Tse LY, Li H, Chan PC, Xu S, Xiao W, Kung HF, Krissansen GW, Fan ST. Long-term expression of angiostatin and suppression of liver metastatic cancer. Hepatology 2003, 37:1451-61.(IF 10.4)
u Li XY, Xu RA, Wang GJ, Xie HT, Zhao XC, Chen M. Effects of rAAV/rSTAP on mRNA Lever of interstitial collagenase in rat stellate cell. Chin J Clin Pharmacol Ther 2004, 9 (11):1236-8.
u Cai KX, Sham MH, Zheng DX, Xu RA*. Anti-HBV medicine and treatment. Chinese Journal of Internal Medicine 2003, 50:744-6.
u Chen Y, Luk KDK, Cheung KMC, Xu RA*, Lin M, Lu WW, Leong JCY, Kung HF. Gene therapy for new bone formation using an adeno-associated viral bone morphogentic protein-2. Gene Therapy 2003, 10:1345-53.(IF 5.3)
u Xu RA*, Cai KX, Zheng D, Ma H, Xu S, Fan ST. Molecular therapeutics of HBV. Curr Gene Ther 2003, 3(4): 341-55. (IF 3.68)
u Shi J, Zheng DX, Man K, Fan ST, XU RA*. TRAIL: A potential agent for cancer therapy. Curr Mol Med 2003, 3: 727-736.(IF4.9)
u Ma H, Xu RA, Cheng H, Kuo HS, During MJ, Fang RH. Gene transfer into human keloid tissue with adeno-associated virus vector. J Trauma 2003, 54 (3): 569-573.
u Cai, KX, Sham MH, Tam P, Lam WK, Xu RA*. Lung cancer gene therapy. Gene Ther Mol Biol 2003, 7:255-72.
u Xu RA*, Li H, Tse L, Kung HF, Lu H, Lam KSL. Diabetes gene therapy: potential and challenges. Curr Gene Ther 2003, 3(1):65-83. (IF 3.68).
u Diao Y, Xu RA, Wang GJ, Zhao XC. Adeno-associated virus mediated expression of human erythropoietin in vitro. Acta Pharmacol Sin 2002, 23 (1): 55-58.
[PMID: 11860738] (IF0.5)
u Jung SC, Han IP, Limaye A, Xu RA, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P. Adeno-associated viral vector-mediated gene transfer results in log-term enzymatic and functional correction in multiple organs of fabric mice. Proc Natl Acad Sci USA 2001, 98: 2676-81.(IF 10.5)
u Mastakov M, Baer C, Xu RA, Fitzsimons H, During MJ. Combined injection of AAV with manitol into rat brain. Mol Ther 2001, 3: 225- 32. (IF 6.1)
u Xu RA, Janson CG, Mastakov M, Lawlor P, Young D, Mouravlev A, Fitzsimons J, Choi KL, Ma H, Dragunow M, Leone P, Chen Q, Dicker B and During MJ. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 2001, 8:1323-32.(IF 5.6)
u During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons H, Poulsen D, Leone P, Xu RA, et al An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000, 287: 1453-60. (IF 29.6)
u Dragunow M, Xu R, Walton M, Woodgate A, Lawlor P, MacGibbon GA, Young D, Gibbons H, Lipski J, Muravlev A, Pearson A, During M. c-Jun promotes neurite outgrowth and survival in PC12 cells. Mol Brain Res 2000, 83(1-2): 20-33.(IF 2.1)
u During MJ, Xu RA, Young D, Kaplitt M, Sherwin R, Leone P Peroral gene therapy of lactose in tolerance using an adeno-associated virus vector. Nat Med 1998, 4: 1131-6.(IF 30.2)
u 许瑞安 医用纳米与基因药物口服化的探索 中国药理学与药物治疗学.2007,12: 1092-1097.54. [核心期刊]
u 史娟, 刘彦信, 刘士廉, 许瑞安, 郑德先. 腺相关病毒介导Smac和DR5单链抗体表达对抑制肿瘤细胞生长的作用；中华医学杂志 2006, 86(26):1857-9. (SCI)
u 许瑞安*, 刁勇, 谢海棠. 基因药物在临床上的最新应用与研发.中国药理学与药物治疗学 2006, 11: 1092-7.
u 王启钊，吕颖慧，刁勇，许瑞安* 干细胞的分裂模式与肿瘤干细胞形成之间的关系中国生化药物学杂志 2008 (in press)
u 曾庆友，曾明荣, 许瑞安* 对氧甲基肉桂酸乙酯一锅式绿色合成法 精细化工 2008, 28 (2)：192-4.
u 刁勇，局海亮, 许瑞安. 单环刺螠抗血栓组分的分离纯化和药效学研究. 中国生化药物学杂志 2007；3：199-200
u Li H，Xu RA* Cell replacement therapy in Parkinson's disease NEURS （in press）
u 舒静波，刁勇，许瑞安* 腺病毒-腺相关病毒嵌合纳米载体研究进展 华大学报 2008，第2 期。[核心期刊]
u 曾庆友，曾明荣, 许瑞安* 对氧甲基肉桂酸甲酯一锅式绿色合成法 合成化学 2007, 15 (10)：163-4。
u 李华 许瑞安* 纤溶活性的药学鉴测方法 中国药理学与药物治疗学.2008, （in press） [核心期刊]
